-+ 0.00%
-+ 0.00%
-+ 0.00%

Daré Bioscience Receives U.S. Patent For Its Pharmaceutical Compositions Formulated For Topical Application Comprising Lopinavir, Ritonavir To Treat Cervical Pathologies

Benzinga·09/28/2026 12:21:09
Listen to the news

Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the issuance of U.S. Patent No. 12,678,439, titled "Lopinavir and Ritonavir for the Treatment of Cervix Disorders," which covers pharmaceutical compositions formulated for topical application comprising lopinavir and ritonavir for the treatment of HPV-related cervical pathologies.